Department of Oncology, Wayne State University and Barbara Ann Karmanos Cancer Center, Detroit, MI, USA.
BioDrugs. 2011 Dec 1;25(6):365-79. doi: 10.2165/11595950-000000000-00000.
Bispecific antibodies (BiAbs) offer a unique opportunity to redirect immune effector cells to kill cancer cells. BiAbs combine the benefits of different binding specificities of two monoclonal antibodies (mAbs) into a single construct. This unique feature of BiAbs enables approaches that are not possible with single mAbs. Advances in antibody engineering and antigen profiling of malignant cells have led to the development of a number of BiAb formats and their combinations for redirecting effector cells to tumor targets. There have been significant advances in the design and application of BiAbs for intravenous and local injection.The initial barrier of cytokine storm has been partially overcome by more recent constructs that have improved clinical effectiveness without dose-limiting toxicities. Since the recent revival of BiAbs, there has been multiple, ongoing, phase I/II and III trials, and some promising clinical outcomes have been reported in completed clinical studies. This review focuses on arming T cells with BiAbs to create the 'poor man's cytotoxic lymphocyte'.
双特异性抗体（BiAbs）为重新定向免疫效应细胞杀伤癌细胞提供了独特的机会。BiAbs 将两种单克隆抗体（mAbs）的不同结合特异性的优势结合到一个单一的构建体中。BiAbs 的这种独特特性使单 mAbs 无法实现的方法成为可能。抗体工程和恶性细胞抗原分析的进展导致了许多 BiAb 格式及其组合的发展，用于将效应细胞重新定向到肿瘤靶标。在设计和应用 BiAbs 进行静脉内和局部注射方面取得了重大进展。通过最近的构建体部分克服了细胞因子风暴的最初障碍，这些构建体在没有剂量限制毒性的情况下提高了临床疗效。自 BiAbs 最近复兴以来，已经进行了多项正在进行的 I/II 期和 III 期试验，并且在已完成的临床研究中报告了一些有希望的临床结果。本综述重点介绍了用 BiAbs 武装 T 细胞以产生“穷人的细胞毒性淋巴细胞”。
